Join to View Full Profile
55 Cambridge Pkwy"# Genzyme"Cambridge, MA 02142
Phone+1 617-761-8848
Fax+1 617-761-8925
Are you Dr. Hsu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Frank Hsu, MD is an oncologist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Massachusetts and Connecticut.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1990 - 1995
University of California (San Francisco)Residency, Internal Medicine, 1987 - 1990
Harvard Medical SchoolClass of 1987
Certifications & Licensure
CT State Medical License 1996 - 2025
MA State Medical License 2005 - 2025
Publications & Presentations
PubMed
- A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.Andrew H Ko, Joseph Chao, Marcus S Noel, Veena Shankaran, Davendra Sohal
Cancer Research Communications. 2025-02-01 - 2 citationsNeoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.Maira Soto, Erin L Filbert, Hai Yang, Stephanie Starzinski, Alec Starzinski
Cancer Research Communications. 2024-01-25 - 10 citationsA Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progres...Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo
Clinical Cancer Research. 2024-01-05
Press Mentions
Chutes & Ladders—Former FDA Commissioner Hahn Takes Interim CMO Role at YourBio HealthSeptember 10th, 2021- Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical OfficerSeptember 9th, 2021
- Oncternal Therapeutics : Cirmtuzumab Poster Presented at ASH 2020 Virtual Annual MeetingDecember 7th, 2020
- Join now to see all
